Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?

Journal Article (Journal Article;Review)

The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people and caused tremendous morbidity and mortality worldwide. Effective treatment for coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 infection is lacking, and different therapeutic strategies are under testing. Host humoral and cellular immunity to SARS-CoV-2 infection is a critical determinant for patients' outcomes. SARS-CoV-2 infection results in seroconversion and production of anti-SARS-CoV-2 antibodies. The antibodies may suppress viral replication through neutralization but might also participate in COVID-19 pathogenesis through a process termed antibody-dependent enhancement. Rapid progress has been made in the research of antibody response and therapy in COVID-19 patients, including characterization of the clinical features of antibody responses in different populations infected by SARS-CoV-2, treatment of COVID-19 patients with convalescent plasma and intravenous immunoglobin products, isolation and characterization of a large panel of monoclonal neutralizing antibodies and early clinical testing, as well as clinical results from several COVID-19 vaccine candidates. In this review, we summarize the recent progress and discuss the implications of these findings in vaccine development.

Full Text

Duke Authors

Cited Authors

  • Lu, L; Zhang, H; Zhan, M; Jiang, J; Yin, H; Dauphars, DJ; Li, S-Y; Li, Y; He, Y-W

Published Date

  • December 2020

Published In

Volume / Issue

  • 63 / 12

Start / End Page

  • 1833 - 1849

PubMed ID

  • 33355886

Pubmed Central ID

  • 33355886

Electronic International Standard Serial Number (EISSN)

  • 1869-1889

Digital Object Identifier (DOI)

  • 10.1007/s11427-020-1859-y

Language

  • eng

Conference Location

  • China